Better coronary risk assessment in women

Lancet

Volumn 353, Issue 9165, 1999, Pages 1637-1638

  Silberberg, Jonathan ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PRAVASTATIN; SIMVASTATIN;

CORONARY ARTERY DISEASE; CORONARY RISK; ELECTROCARDIOGRAM; FAMILY HISTORY; FEMALE; HUMAN; MEDICAL ASSESSMENT; NOTE; PRIORITY JOURNAL;

EID: 0033562648     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)00382-1     Document Type: Note

References (15)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
2. Sacks FM et al for the Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-09.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-57.
4. Newnham H. Silberberg J. Women's hearts are hard to break. Lancet 1997; 349 (suppl I): sI3-sI6.
5. de Bacquer D, de Backer G, Kornitzer M, Blackburn H. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 1998; 80: 570-57.
6. Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986; 73: 114-23.
7. Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340: 1221-27.
8. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985; 14: 32-38.
9. Hunt SC, Williams RR, Barlow GK. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis 1986; 39: 809-21.
10. Berwick DM. Cholesterol, children and heart disease. New York: Oxford University Press, 1980:357.
11. Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley M. Risk associated with various definitions of a family history of CHD: the Newcastle Family History Study II. Am J Epidemiol 1998; 147: 1133-39.
12. Pyörälä K, de Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121-61.
13. Garber AM, Browner WS & Hulley SB. Clinical Guideline, part 2: cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996; 124: 518-31.
14. Ramsay LE, Haq IU, Jackson P, et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996; 348: 387-88.
15. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol 1996; 27: 957-1047.